potenti surviv benefit patient dose
scant evid deepen anti-tumor activ time
comment stock weak
review look ahead
sit pretti updat phase result reiter
look fda feedback hemophilia program quiet
expect posit phase flu vaccin data drive busi
develop result
execut track maintain outperform
lenabasum late-stag program track acr showcas
updat strong presenc expect ahead potenti
analyst certif import disclosur see
in-lin number need significantli outperform justifi
amphora track launch year sti data around
takeaway oncolog expert interview
review sober reset portfolio updat
model pt
review phase polarisdmd top-lin readout pt
review renew vigor focu three clinic
program pt
wait clariti time os data breast
cancer overhang like lift come week
updat anticip data
healthi beat revenu put sale guidanc
lower pt sluggish maintain outperform
report fully-commerci stori march forward
strateg prioriti track
new ceo strategic-realign effort deliv result
perform upgrad outperform
first pass highlight abstract releas
review translat
quick take first glanc
report stori remain track
hope first glanc myelofibrosi anticip us
approv lu -thal
report solid updat guidanc
initi signal hint larg opportun mf
updat explor sever avenu cancer beyond
first glanc
review focu sharpen pegasu near
quarter maintain outperform
updat seek proof-of-concept ipsc-nk
deliv earli sign clinic activ
feedback manag investor lunch
continu progress
strong tug war outlook continu
updat allogen entri bcma car-t frenzi
updat highlight progress sever front
updat look ahead non-invas nash dynam
report follow-up confer call
review pipelin commerci execut continu pt
snda file cholangiocarcinoma delay
rais path upsid
renew new initi interest
eye aurora phase catalyst preview
robust financ ink royalti pharma
strong shipment pipelin focu
updat outlin event horizon
updat late break melanoma updat schedul
present
first clinic updat orphan drug program ntm
expect phase studi track
first glanc
consider ahead quarterli result
acut spin iv meloxicam come back playour
thought valuat
beigen deal open gateway chines oncolog opportun
consider ahead result
potenti surviv benefit patient dose scant evid deepen anti-tumor activ
ntgn present two poster meet includ matur subgroup
studi import takeaway includ median melanoma cohort reach month line
expect modest reduct nsclc top line report juli month vs month previous report
improv surviv addit bladder cancer patient although surviv month
subgroup significantli longer month seen previou studi monotherapi note
anti-tumor activ cohort achiev end month six dose week separ ntgn
confirm previou timelin cta file
comment stock weak
share today follow post fda maud advers event report databas patient death
slim basal-iq
caus death unknown per coron patient blood glucos reportedli low around time
speak compani manag reason believ pump malfunct reason death
remind us one file maud report familiar case patient death
pump note pump ship past four year abl
updat basal-iq technolog patient wish almost pump ship overal
past four year
follow convers manag buyer morn weak
top stori earn season finish univers number strong report
beat expect manag care group complet strong quarter saw sentiment final turn favor
meanwhil addu also report good result post-acut name remain favor due robust growth
review look ahead
sarepta report result provid updat develop commerci activ
backdrop golodirsen updat nine-month function data three patient enrol on-going
phase studi sarepta remain focus object outlin manag street focu
develop pipelin name highlight role golodirsen could
medium term updat regulatori action remain potenti catalyst keep vigil progress
commerci suppli develop feasibl outlin timelin could put test
updat model stay neutral
sit pretti updat phase result reiter outperform
thursday announc earn review recent progress present featur updat
result kadmon phase trial chronic graft-versus-host diseas cgvhd well epidemiolog studi
diseas six month addit follow-up orr trial increas mdor
extend week week full popul clinic updat reaffirm convict kadmon
pivot rockstar studi expect yield earli result later month excel chanc hit primari
endpoint addit announc partnership develop china
success commerci could provid upsid estim reiter outperform rate pt
report adj-ep vs opco/street consensu estim beat aid
low tax rate hospic price concess set asid move part hh trend strong
admiss grow furthermor rais ep guidanc vs
vs rais ep estim focu remain
outlook pdgm follow last week favor rule remain optimist opportun
potenti disrupt smaller provid hurdl off-set highli manag result rais
estim price target
report result modestli higher consensu revenu estim manag
maintain revenu guidanc indic expect trend higher end top-line guidanc rang
increas year-end cash flow guidanc importantli continu invest
 pursu variou chronic episod indic tradipit await outcom litig
fda relat long-term non-human primat toxicolog studi remain sidelin tradipit regulatori
legal hurdl resolv manag howev note potenti upsid favor regulatori action hetlioz
smith-mageni syndrom file anticip
look fda feedback hemophilia program quiet result
cbio present unev financi result continu view outcom marzaa end-of-phas ii
meet next catalyst follow present complet phase iib dataset dalcaa subq factor ix
compani two present marzaa meet decemb view either materi catalyst
cbio share
expect posit phase flu vaccin data drive busi develop result
report unev financi result reiter plan disclos top-line result phase
nanoflu studi prevent season influenza older adult base studi size time first patient
dose expect top-line data februari march view studi low risk base strong phase ii data expect
posit data may support busi develop activ includ potenti sale compani end quarter
avail view adequ fund compani top-line nanoflu result revis ep
outlook account modest reduct expect spend
execut track maintain outperform
teva report result slightli consensu top-lin estim bottom line due
higher tax manag narrow full-year guidanc provid insight three key lever turnaround includ
restructur leverag reduct growth driver given cost reduct almost realiz earli evid improv
busi fundament moder copaxon declin stabil gener leverag ratio creep await
updat earli next year addit margin improv opportun manufactur optim leverag manag
top-line growth driver pipelin asset anticip litig uncertainti continu believ continu
evid oper improv may posit teva refin debt combin improv
fundament increas investor confid stock
lenabasum late-stag program track acr showcas long-term treatment experi
report net loss vs clinic readout agonist lenabasum scleroderma ph
cystic fibrosi registr ph fulli enrol remain track next summer first-in-human safeti studi
peripherally-restrict invers agonist report commerci plan buildout begun
anticip launch lenabasum note pharma rise interest endocannabinoid space
exemplifi early-stag cb modul lundbeck takeda roch look forward updat ole result
among lenabasum data acr weekend believ build industry-lead endocannabinoid
therapeut compani share deepli undervalu market opportun lenabasum alon reiter
report ep beat though rev slightli behind estim vs within guid
partial contract termin follow client vendor lost adher busi maintain
core mtm dosem work client unusu larg size contract pressur guid see minim
impact contract rev slate importantli total similar contract
present minim risk futur recurr pace hum organ growth ytd cross-sel
across custom new locat contract top today provid good visibl reiter
updat strong presenc expect ahead potenti launch
thursday global blood report earn review recent progress voxelotor februari pdufa date rapidli
approach global blood heavili engag us launch prepar field team on-board
believ compani posit hit ground run assum voxelotor receiv acceler approv
compani plan present eight abstract includ sever post-hoc analys believ collect point
long-term benefit associ address hemolyt anemia compon scd global blood outlin multipl
post-approv confirmatori trial start pediatr patient elev stroke risk believ
compani well capit support success launch reiter outperform pt
in-lin number need significantli outperform justifi valuat
report number revenu slightli higher consensu roughli
line estim gross margin slightli lag estim gross margin stage
inher unreli metric quarterli perform compani rais guidanc margin revenu
expect rang margin tweak forecast
number unchang although op-ex estim increas significantli stock current trade
estim forward sale need signific step-up quarterli number consensu estim justifi
premium valuat
amphora track launch year sti data around corner
net loss vs lower amphora nda pregnanc prevent remain track
resubmit ye impli potenti approv launch newli commiss market research provid
increment definit around amphora target market sale team hire anticip begin month
see top-lin result amphora phase prevent sti believ could offer upsid surpris
given neglig valu current attribut could meaning market expans opportun reiter
outperform expect share grind higher amphora advanc market becom commerci stori
takeaway oncolog expert interview
interview dr hatim husain discuss emerg target treatment oncolog dr husain board-certifi medic
oncologist associ professor depart medicin uc san diego school medicin optimist
kra pathway show promis efficaci hras-target
tipifarnib also show impress result strong durabl hnscc limit option bempeg
melanoma dr husain think bar high pfs/o data need compet tki
cabozantinib tucatinib may wide use combo i-o given good toler blood-brain
barrier penetr dr husain also note target mutual exclus
express make import option refractori inelig patient mani cancer type especi nsclc
review sober reset portfolio updat model pt
strongbridg report result provid corpor updat program midst transit
overal busi ad color updat guidanc phase logic readout recorlev cush
discontinu sale agreement novo follow news reassess valuat compani pipelin
adjust estim model maintain high convict recorlev franchis signific
clinic potenti cush treatment paradigm adjust estim time valuat keveyi
macrilen franchis spite recent disappoint event continu view under-valued name
potenti transform inflect point expect
review phase polarisdmd top-lin readout pt
catabasi provid financi corpor updat phase polarisdmd trial edasalonex
dmd complet enrol septemb catb guid pivot readout follow nda file
assum posit result although still four quarter away readout mani increment updat
baselin characterist polarisdmd patient preclin data limb-girdl muscular dystrophi type
commerci launch detail edasalonex new data open-label phase extens
studi anim data edasalonex becker md lower pt due sector multipl
compress updat model stay bullish
review renew vigor focu three clinic program pt
cellecti provid updat hed investor confer call clinic
process recruit dose patient phase trial period
manufactur snafu slowli develop clinic progress believ
renew focu cll order fulfil vast potenti type medic technolog specif first patient
dose relapsed/refractori multipl myeloma mm upcom dose first patient
occur next week believ could good year cll reduc price target due
sector multipl compress stay bullish
wait clariti time os data breast cancer overhang like lift come week
report financi result re-affirmed timelin us regulatori file oraxol ak program
manag complet end-of-phas discuss ak interact oraxol on-going
time fda discuss may impact scope phase metastat breast cancer data present san
antonio breast cancer meet expect share remain range-bound manag clarifi whether
os data present san antonio posit note payor outreach suggest price similar
launch price abraxan achiev oraxol despit gener competit believ busi develop
particularli oraxol partner asia may extend cash balanc beyond
updat anticip data
provid updat financi result busi highlight net loss better
estim result cash loss better estim net loss guidanc still
includ share-bas comp estim annual cash burn next year would
provid sever year runway encourag progress prasinezumab parkinson diseas
data part attr amyloidosi data updat cohort
total continu work preclin tau antibodi program partner celg updat model
actual guidanc
nektar report financi result revis guidanc provid pipelin updat includ multipl catalyst
sever promis early-stag asset other well nda-fil
anticip launch think investor mostli concern bempeg combo trial
checkpoint inhibitor bempeg follow-up present weekend orr/cr/pf data
anticip collabor on-going plan expand bempeg registr trial howev
decreas slightli narrow spend guidanc view
reflect uncertainti late-stag trial initi and/or potenti prioriti shift earlier-stag trial updat model
actual drive new pt
healthi beat revenu put sale guidanc sight
report revenu beat outlook consensu estim reiter guidanc
revenu least believ street understand concern larg step-up least
meet guidanc vs believ near-term focu overlook healthi long-term growth trend
continu gain market share increas payor coverag in-network cover million live
diversifi revenu biopharma partner total nearli separ began offer proactiv screen
univers vermont health network studi genet test effect gener popul diversifi
revenu catalyst includ potenti revenu pre-announce updat
lower pt sluggish maintain outperform
follow result guidanc revis vs lower price target
model flatter revenu curv vs prior estim manag continu improv payor
coverag believ revenu uptak could lag meaning sinc chang prescrib habit could take longer
origin anticip despit lower revenu estim pt maintain outperform rate continu
view rocklatan rhopressa clinic differenti agent time could becom import therapeut
altern ophthalmologist armamentarium manag elev intra-ocular pressur manag maintain
peak us revenu guidanc lower peak estim vs
ortx provid updat also announc anticip registration-en data ada-scid
program await detail encourag abstract disclosur indic
